Ani Pharmaceuticals (ANIP) Research & Development (2016 - 2025)
Ani Pharmaceuticals (ANIP) has disclosed Research & Development for 16 consecutive years, with $12.3 million as the latest value for Q4 2025.
- Quarterly Research & Development fell 26.34% to $12.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.7 million through Dec 2025, up 15.89% year-over-year, with the annual reading at $51.7 million for FY2025, 15.89% up from the prior year.
- Research & Development hit $12.3 million in Q4 2025 for Ani Pharmaceuticals, roughly flat from $12.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $16.6 million in Q4 2024 to a low of $2.5 million in Q3 2021.
- Historically, Research & Development has averaged $8.2 million across 5 years, with a median of $7.5 million in 2022.
- Biggest five-year swings in Research & Development: plummeted 53.22% in 2021 and later surged 211.77% in 2022.
- Year by year, Research & Development stood at $3.1 million in 2021, then surged by 66.31% to $5.2 million in 2022, then skyrocketed by 88.95% to $9.9 million in 2023, then soared by 68.7% to $16.6 million in 2024, then fell by 26.34% to $12.3 million in 2025.
- Business Quant data shows Research & Development for ANIP at $12.3 million in Q4 2025, $12.3 million in Q3 2025, and $16.5 million in Q2 2025.